Majority Shareholder Approves 150% Increase in Authorized Shares for FOXO Technologies

summarizeSummary

FOXO Technologies' majority shareholder, controlled by the CEO, approved a significant increase in authorized common stock from 10 billion to 25 billion shares, signaling potential for substantial future dilution.

check_boxKey Events

• Authorized Share Increase Approved

  The majority shareholder approved an amendment to increase authorized Class A Common Stock from 10,000,000,000 shares to 25,000,000,000 shares.

• CEO-Controlled Majority

  The approval was granted by Rennova Health, Inc., which is controlled by FOXO's CEO and holds approximately 97.59% of the company's voting rights.

• Follows Preliminary Filing

  This approval follows the preliminary Information Statement on Schedule 14C filed on April 1, 2026, which initially disclosed the proposed increase.

• Future Dilution Potential

  The substantial increase in authorized shares provides the company with significant headroom for future equity issuances, likely leading to further dilution for existing shareholders.

auto_awesomeAnalysis

This 8-K confirms the formal approval by the majority shareholder of the previously disclosed plan to increase authorized common stock by 150%. For a micro-cap company like FOXO Technologies, such a substantial increase in authorized shares typically precedes significant dilutive capital raises, which could further pressure the stock price. Investors should anticipate future equity offerings to fund operations, given the company's low stock price and small market capitalization.